Indium-111-Antimyosin Scintigraphy After Doxorubicin Therapy in Patients with Advanced Breast Cancer

• Published in: The Journal of nuclear medicine (1978) Vol. 31; no. 12; pp. 1965 - 1969
• Main Authors: Estorch, Montserrat, Carrio, Ignasi, Berna, Lluis, Martinez-Duncker, Carlos, Alonso, Carmen, Germa, Josep-Ramon, Ojeda, Belen
• Format: Journal Article
• Language: English
• Published: Reston, VA Soc Nuclear Med 01-12-1990; Society of Nuclear Medicine
• Subjects: 550601 - Medicine- Unsealed Radionuclides in Diagnostics; Adult; Aged; ANTIBODIES; Antibodies, Monoclonal; BETA DECAY RADIOISOTOPES; Biological and medical sciences; BODY; Breast Neoplasms - drug therapy; Breast Neoplasms - physiopathology; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHEMOTHERAPY; COUNTING TECHNIQUES; DAYS LIVING RADIOISOTOPES; DIAGNOSIS; DIAGNOSTIC TECHNIQUES; DISEASES; Doxorubicin - adverse effects; Doxorubicin - therapeutic use; ELECTRON CAPTURE RADIOISOTOPES; Female; GLANDS; HEART; Heart - diagnostic imaging; Heart - drug effects; Heart - physiopathology; Humans; INDIUM 111; INDIUM ISOTOPES; Indium Radioisotopes; INTERMEDIATE MASS NUCLEI; Investigative techniques, diagnostic techniques (general aspects); ISOMERIC TRANSITION ISOTOPES; ISOTOPE APPLICATIONS; ISOTOPES; Male; MAMMARY GLANDS; Medical sciences; Middle Aged; MINUTES LIVING RADIOISOTOPES; MONOCLONAL ANTIBODIES; MUSCLES; MYOCARDIUM; NEOPLASMS; NUCLEI; ODD-EVEN NUCLEI; Organometallic Compounds; ORGANS; PATIENTS; RADIOIMMUNODETECTION; RADIOIMMUNOSCINTIGRAPHY; RADIOISOTOPE SCANNING; RADIOISOTOPES; RADIOLOGY AND NUCLEAR MEDICINE; Radionuclide Imaging; SCINTISCANNING; Stroke Volume - drug effects; Stroke Volume - physiology; THERAPY; TRACER TECHNIQUES; Ventricular Function, Left - drug effects; Ventricular Function, Left - physiology; Mammary gland diseases; Tumor; Scintigraphy; Indium; Radiopharmaceuticals
• ISSN: 0161-5505; 1535-5667

Indium-111-antimyosin (111In-antimyosin) scans were performed in 20 women with advanced breast cancer after 10 cycles of chemotherapy consisting of cyclophosphamide, 5-fluorouracil and doxorubicin (total cumulative dose of doxorubicin of 500 mg/m2). Antimyosin uptake in the myocardium was quantified by means of a heart-to-lung ratio (HLR). Antimyosin uptake in the myocardium was observed in 17/20 (85%) patients, and HLR after chemotherapy was 1.86 +/- 0.25. Left ventricular ejection fraction (EF) was determined before and after chemotherapy. Patients with decreased EF (8/20, 40%) presented with more intense antimyosin uptake (HLR of 2.11 +/- 0.10 versus 1.70 +/- 0.16 (p = 0.01]. HLR values correlated with EF values after chemotherapy (r = -0.47, p less than 0.05). Positive antimyosin studies after chemotherapy including doxorubicin, indicate the presence of myocardial damage in these patients. Antimyosin studies are a sensitive method to detect myocyte damage in patients after doxorubicin therapy.